Progressive multifocal leukoencephalopathy and natalizumab

Journal of Neurology

Volumn 258, Issue 11, 2011, Pages 1920-1928

  Hellwig, Kerstin ^a   Gold, Ralf ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

IRIS; Multiple sclerosis; Natalizumab; Plasmapheresis

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; BETA INTERFERON; CARMUSTINE; CIDOFOVIR; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACARBAZINE; DACLIZUMAB; EFALIZUMAB; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MEFLOQUINE; MIRTAZAPINE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; NATALIZUMAB; OKT 3; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TACROLIMUS; UNINDEXED DRUG;

ANTIVIRAL THERAPY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; CONTRAST ENHANCEMENT; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIOLOGICAL DATA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; JC VIRUS; LABORATORY TEST; LONG TERM CARE; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84855566011     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6116-8     Document Type: Review

References (57)

1. Polman CH, O'Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:889-910
2. Miller DH, Soon D, Fernando KT et al (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68:1390-1401
3. Munschauer F, Giovannoni G, Lublin F et al (2008) Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability. Mult Scler 14(Suppl 1):S168
4. Hutchinson M, Kappos L, Calabresi PA, For the AFFIRM and SENTINEL Investigators et al (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 256:405-415
5. Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8:254-260
6. Balcer L, Galetta S, Calabresi P et al (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68:1299-1304
7. Rudick R, Miller D, Hass S et al (2007) Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 62:335-346
8. Kleinschmidt-DeMasters BK, Tyler KL (2005) Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353:369-374
9. Langer-Gould A, Atlas SW, Green AJ et al (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375-381
10. Van Assche G, Van Ranst M, Sciot R et al (2005) Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353:362-368
11. Yousry T, Major E, Ryschkewitsch C et al (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354:924-933
12. Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N Eng J Med 354:911-923
13. Clifford DB, De Luca A, Simpson DW et al (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons learned from 28 cases. Lancet Neurol 9:438-446
14. Schröder A, Lee DH, Hellwig K et al (2010) Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis. Arch Neurol 67(11):1391-1394
15. Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295-303
16. Weber T (2008) Progressive multifocal leukoencephalopathy. Neurol Clin 26:833-854
17. Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R (2010) JC virus infection of the brain. AJNR Am J Neuroradiol 31(9): 1564-1576
18. Calabrese LH, Molloy ES, Huang DR, Ransohoff RM (2007) Progressive multifocal leukoencephalopathy in rheumatic diseases. Arthritis Rheum 56:2116-2128
19. Carson KR, Focosi D, Major EO et al (2009) Monoclonal antibody-associated progressive multifocal leukoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816-824
20. Dang X, Koralnik IJ (2006) A granule cell neuron-associated JC virus variant has a unique deletion in the VP1 gene. J Gen Virol 87(Pt 9):2533-2537
21. Wüthrich C, Dang X, Westmoreland S, McKay J, Maheshwari A, Anderson MP, Ropper AH, Viscidi RP, Koralnik IJ (2009) Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 65(6):742-748
22. Lima MA, Drislane FW, Koralnik IJ (2006) Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66(2):262-264
23. Giancola ML, Rizzi EB, Lorenzini P et al (2008) Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables. AIDS Res Hum Retroviruses 24:155-162
24. Warnke C, Menge T, Hartung HP, Racke MK, Cravens PD, Bennett JL, Frohman EM, Greenberg BM, Zamvil SS, Gold R, Hemmer B, Kieseier BC, Stüve O (2010) Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 67(8):923-930 Review
25. Chen Y, Bord E, Tompkins T et al (2009) Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361:1067-1074
26. Rinaldi L, Rinaldi F, Perini P, Calabrese M, Seppi D, Grossi P, Mattisi I, Barzon L, Mengoli C, Sanzari M, Palú G, Gallo P (2010) No evidence of JC virus reactivation in natalizumab-treated multiple sclerosis patients: an 18 month follow-up study. J Neurol Neurosurg Psychiatry 81(12):1345-1350
27. Zohren F, Toutzaris D, Klärner V, Hartung HP, Kieseier B, Haas R (2008) The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 111(7):3893-3895
28. Warnke C, Smolianov V, Dehmel T, Andrée M, Hengel H, Zohren F, Arendt G, Wiendl H, Haas R, Hartung HP, Adams O, Kieseier BC (2011) CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler 17(2):151-156
29. Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, Lindå H, Ziemssen T, Baranzini SE, Käll T-B, Bengel D, Olsson T, Gold R, Chan A (2011) Functional energetics of CD4+ -cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One 6(4):e18506
30. Clifford DB, Yiannoutsos C, Glicksman M et al (1999) HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52:623-625
31. DeLuca A, Giancola ML, Annassari A et al (2000) The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182: 1077-1083
32. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53(5):1840-1849
33. Hall CD, Dafni U, Simpson D et al (1998) AIDS Clinical Trials Group 243 Team. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 338:1345-1351
34. DeLuca A, Giancola ML, Ammassari A et al (2000) Cidofovir added to HAART improved virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy. AIDS 14:F117-F121
35. DeLuca A, Giancola ML, Ammassari A et al (2001) Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J Neurovirol 7:364-368
36. Przepiorka D, Jaeckle KA, Birdwell RR et al (1997) Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 20:983-987
37. Re D, Bamborschke S, Feiden W et al (1999) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23:295-298
38. Huang SS, Skolasky RL, Dal Pan GJ et al (1998) Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol 4:324-332
39. Geschwind MD, Skolasky RI, Royal WS, McArthur JC (2001) The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 7:353-357
40. Nath A, Venkataramana A, Reich DS et al (2006) Progression of progressive multifocal leukoencephalopathy despite treatment with β-interferon. Neurology 66:149-150
41. Kunschner L, Scott TF (2005) Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65:1510
42. Venkataramana A, Pardo CA, McArthur JC, Kerr DA, Irani DN, Griffin JW, Burger P, Reich DS, Calabresi PA, Nath A (2006) Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology 67(3):383-388
43. Tan K, Roda R, Ostrow L et al (2009) PML-IRIS in HIV infection. Clinical manifestations and treatment with steroids. Neurology 72:1458-1464
44. Biogen Idec. Data on file
45. Bozic C, Christiano LM, Hyde R et al (2010) Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis. Mult Scler 16(suppl 10):S315
46. Stangel M, Sorensen PS, Petersen T et al (2009) Natalizumab utilization and safety in the TYGRIS program in the European Union and Canada. Mult Scler 15(suppl 2):S234
47. Khatri B, Man S, Giovannoni G et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72:402-409
48. Wenning W, Haghikia A, Laubenberger M et al (2009) Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361:1075-1080
49. Ryschkewitsch CF, Jensen PN, Monaco MC, Major EO (2010) JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab. Ann Neurol 68(3):384-391
50. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20): 4834-4840
51. O'Connor PW, Goodman A, Kappos L et al (2009) Return of disease activity with cessation of natalizumab therapy in patients with multiple sclerosis. Mult Scler 15(suppl 2):S240-S243
52. Killestein J, Vennegoor A, Strijbis EM et al (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68:392-395
53. Clinicaltrials.gov Web site (2010) Trial NCT00746941. http://www.clinicaltrials.gov/ct2/show/NCT01071083?term=biogen?idec? restore&rank=1. Accessed 9 November 2010
54. European Agency for the Evaluation of Medicinal Products (2010) TYSABRI® summary of product characteristics. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/000603/WC500044686.pdf. Accessed 19 August 2010
55. Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431-444
56. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebocontrolled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401
57. Kappos L, Bates D, Edan G et al (2011) Natalizumab in patients with multiple sclerosis: treatment recommendations. Lancet Neurol (in press)